September 21, 2011

PositiveID develops biological detection capabilities

PositiveID Corporation has declared the development of its biological detection capacities to include the detection of H5N1 virus which results in avian flu.

PositiveID has the biological capability to detect any virus, bacteria or toxin in an environmental or clinical environment through its MicroFluidic Systems ("MFS") subsidiary.

PositiveID is completing a test to rapidly and cost-effectively identify the mutant strain of H5N1 and expects to have its laboratory development completed in the fourth quarter of 2011. The company has created and proven to have both highly modular, smart, "plug and play" components and integrated solutions for practical, high utility biological analysis applications. Its products are able to rapidly process complex samples with a high level of sensitivity and accuracy, the company said.

William J. Caragol, PositiveID's CEO, said, "Our biological sample preparation and detection platform is highly adaptable, and the process of expanding our detection capabilities to test for new viruses and bacteria can be accomplished in a very short period of time. Therefore, not only can we be ready to test for this mutant strain of bird flu very quickly, but we can be ready for future outbreaks, whether it is swine flu or some other pandemic virus. Our unique solutions reduce costs, increase reliability and produce timely results, which is of critical importance when diagnosing pandemic viruses to improve outbreak containment measures."